Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 3
Chunk 2
---
.                                                                                                      

  If we fail to comply with healthcare laws, we could face substantial penalties and our business, financial condition and results of operations could be adversely affected.                           
  We may become subject to U. S. federal and state forfeiture laws which could negatively impact our business operations.                                                                               
  Failure to comply with health and data protection laws and regulations could lead to government enforcement actions, private litigation, and/or adverse publicity.                                    
  We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve regulatory approval before we do or d...  

  If the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer.  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Risks Related to Reliance on Third Parties

  We may seek to enter into additional collaborations and other similar arrangements and may not be successful in entering into new arrangements, and even if we are, we may not realize the benefi...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Collaborative relationships with third parties could cause us to expend significant resources and incur substantial business risk with no assurance of financial return.  

  We rely on third parties to assist in conducting our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily.  
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Our use of third parties to manufacture and develop our product candidates for preclinical studies and clinical trials may increase the risk that we will not have sufficient quantities of mater...  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  We have no sales, distribution, or marketing experience, and may invest significant financial and management resources to establish these capabilities.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Risks Related to Our Intellectual Property

  If we are unable to obtain and maintain effective patent rights for our product candidates or any future product candidates, we may not be able to compete effectively in our markets.  
 ─────────────────────────────────────────────────